Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth
Pregnancy-related complications such as pre-eclampsia and preterm birth now represent a notable burden of adverse health. Pre-eclampsia is a hypertensive disorder unique to pregnancy. It is an important cause of maternal death worldwide and a leading cause of fetal growth restriction and iatrogenic...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/16/5/10952 |
id |
doaj-0c8f6ba1f8204014beb275d8c64bcadb |
---|---|
record_format |
Article |
spelling |
doaj-0c8f6ba1f8204014beb275d8c64bcadb2020-11-24T22:22:24ZengMDPI AGInternational Journal of Molecular Sciences1422-00672015-05-01165109521098510.3390/ijms160510952ijms160510952Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm BirthKai P. Law0Ting-Li Han1Chao Tong2Philip N. Baker3China-Canada-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, ChinaChina-Canada-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, ChinaChina-Canada-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, ChinaChina-Canada-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, ChinaPregnancy-related complications such as pre-eclampsia and preterm birth now represent a notable burden of adverse health. Pre-eclampsia is a hypertensive disorder unique to pregnancy. It is an important cause of maternal death worldwide and a leading cause of fetal growth restriction and iatrogenic prematurity. Fifteen million infants are born preterm each year globally, but more than one million of those do not survive their first month of life. Currently there are no predictive tests available for diagnosis of these pregnancy-related complications and the biological mechanisms of the diseases have not been fully elucidated. Mass spectrometry-based proteomics have all the necessary attributes to provide the needed breakthrough in understanding the pathophysiology of complex human diseases thorough the discovery of biomarkers. The mass spectrometry methodologies employed in the studies for pregnancy-related complications are evaluated in this article. Top-down proteomic and peptidomic profiling by laser mass spectrometry, liquid chromatography or capillary electrophoresis coupled to mass spectrometry, and bottom-up quantitative proteomics and targeted proteomics by liquid chromatography mass spectrometry have been applied to elucidate protein biomarkers and biological mechanism of pregnancy-related complications. The proteomes of serum, urine, amniotic fluid, cervical-vaginal fluid, placental tissue, and cytotrophoblastic cells have all been investigated. Numerous biomarkers or biomarker candidates that could distinguish complicated pregnancies from healthy controls have been proposed. Nevertheless, questions as to the clinically utility and the capacity to elucidate the pathogenesis of the pre-eclampsia and preterm birth remain to be answered.http://www.mdpi.com/1422-0067/16/5/10952pre-eclampsiapreterm birthmass spectrometryproteomicsprotein biomarkers |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kai P. Law Ting-Li Han Chao Tong Philip N. Baker |
spellingShingle |
Kai P. Law Ting-Li Han Chao Tong Philip N. Baker Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth International Journal of Molecular Sciences pre-eclampsia preterm birth mass spectrometry proteomics protein biomarkers |
author_facet |
Kai P. Law Ting-Li Han Chao Tong Philip N. Baker |
author_sort |
Kai P. Law |
title |
Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth |
title_short |
Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth |
title_full |
Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth |
title_fullStr |
Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth |
title_full_unstemmed |
Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth |
title_sort |
mass spectrometry-based proteomics for pre-eclampsia and preterm birth |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2015-05-01 |
description |
Pregnancy-related complications such as pre-eclampsia and preterm birth now represent a notable burden of adverse health. Pre-eclampsia is a hypertensive disorder unique to pregnancy. It is an important cause of maternal death worldwide and a leading cause of fetal growth restriction and iatrogenic prematurity. Fifteen million infants are born preterm each year globally, but more than one million of those do not survive their first month of life. Currently there are no predictive tests available for diagnosis of these pregnancy-related complications and the biological mechanisms of the diseases have not been fully elucidated. Mass spectrometry-based proteomics have all the necessary attributes to provide the needed breakthrough in understanding the pathophysiology of complex human diseases thorough the discovery of biomarkers. The mass spectrometry methodologies employed in the studies for pregnancy-related complications are evaluated in this article. Top-down proteomic and peptidomic profiling by laser mass spectrometry, liquid chromatography or capillary electrophoresis coupled to mass spectrometry, and bottom-up quantitative proteomics and targeted proteomics by liquid chromatography mass spectrometry have been applied to elucidate protein biomarkers and biological mechanism of pregnancy-related complications. The proteomes of serum, urine, amniotic fluid, cervical-vaginal fluid, placental tissue, and cytotrophoblastic cells have all been investigated. Numerous biomarkers or biomarker candidates that could distinguish complicated pregnancies from healthy controls have been proposed. Nevertheless, questions as to the clinically utility and the capacity to elucidate the pathogenesis of the pre-eclampsia and preterm birth remain to be answered. |
topic |
pre-eclampsia preterm birth mass spectrometry proteomics protein biomarkers |
url |
http://www.mdpi.com/1422-0067/16/5/10952 |
work_keys_str_mv |
AT kaiplaw massspectrometrybasedproteomicsforpreeclampsiaandpretermbirth AT tinglihan massspectrometrybasedproteomicsforpreeclampsiaandpretermbirth AT chaotong massspectrometrybasedproteomicsforpreeclampsiaandpretermbirth AT philipnbaker massspectrometrybasedproteomicsforpreeclampsiaandpretermbirth |
_version_ |
1725768554456809472 |